FURIN

K.U.LEUVEN R&D

Application Filed: 2001-04-19

Trademark Application Details

Status

601

Dead/Abandoned

ABANDONED - EXPRESS

Research	OneLook Acronym Finder
Serial Number	78059170
Mark Drawing Code	1000: Typeset: Word(s)/letter(s)/number(s)
Domestic Representative	Willy Manfroy
Law Office Assigned	L20
Employee Name	GOLDEN, JAMES B

Timeline

2001-04-19	Application Filed
2003-03-19	Abandon
2003-03-30	Status: Dead/Abandoned
2003-04-21	Location: FILE REPOSITORY (FRANCONIA)
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	K.U.LEUVEN R&D
Entity Statement	University of Leuven
Address	Groot Begijnhof Benedenstraat 59 Leuven Vlaams-Brab BE 3000
Legal Entity Type
Legal Entity State	BE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

Willy Manfroy
97607 Franklin Ridge
Chapel Hill NC 27517

Good, Services, and Codes

International Codes:	1
U.S. Codes:	001,005,006,010,026,046
International Codes:	5
U.S. Codes:	006,018,044,046,051,052
International Codes:	42
U.S. Codes:	100,101

Type Code	Type
GS0011	Genetically engineered animal cells for in vitro production for medical or veterinary use of biological active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, including genetically engineered animals for in vivo production for medical or veterinary use of biologically active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, test-tube manufacture for medical or veterinary use of biologically active recombinant proteins genetically engineered derivatives thereof from a proprotein or precursor protein using a proprotein convertase, biologically active recombinant proteins or genetically engineered derivatives of plasma proteins such as blood clotting factors and albumin, biological active recombinant proteins or genetically engineered derivatives of brain proteins such as neuropeptides, polypeptide hormones and receptors, biologically active recombinant proteins or genetically engineered derivatives of growth and differentiation factors such as for instance members of the TGF- BETA/BMP superfamily, biologically active recombinant proteins or genetically engineered derivatives of growth factor receptors such as the type I insulin-like growth factor receptor, biologically active recombinant proteins or genetically engineered derivatives of viral proteins from viruses, such as for example HIV, Ebola virus, Marburg virus, influenza virus, biologically active recombinant protein or genetically engineered derivatives of toxins e.g. anthrax toxin, biologically active recombinant proteins or genetically engineered derivatives of a variety of enzymes such as metalloproteinases and proprotein convertases, biologically active recombinant proteins or genetically engineered derivatives of several cell-surface receptors, adhesion molecules, signaling proteins and extracelluar-martix proteins, biologically active recombinant proteins or genetically engineered derivatives of proteins or fragments thereof for production of vaccines, biological active recombinant proteins or genetically engineered derivatives of any natural occurring of artificially designed proprotein or precursor protein which requires the action of a proprotein convertase for cleavage into biologically active components

Type Code

Type

GS0011

Genetically engineered animal cells for in vitro production for medical or veterinary use of biological active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, including genetically engineered animals for in vivo production for medical or veterinary use of biologically active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, test-tube manufacture for medical or veterinary use of biologically active recombinant proteins genetically engineered derivatives thereof from a proprotein or precursor protein using a proprotein convertase, biologically active recombinant proteins or genetically engineered derivatives of plasma proteins such as blood clotting factors and albumin, biological active recombinant proteins or genetically engineered derivatives of brain proteins such as neuropeptides, polypeptide hormones and receptors, biologically active recombinant proteins or genetically engineered derivatives of growth and differentiation factors such as for instance members of the TGF- BETA/BMP superfamily, biologically active recombinant proteins or genetically engineered derivatives of growth factor receptors such as the type I insulin-like growth factor receptor, biologically active recombinant proteins or genetically engineered derivatives of viral proteins from viruses, such as for example HIV, Ebola virus, Marburg virus, influenza virus, biologically active recombinant protein or genetically engineered derivatives of toxins e.g. anthrax toxin, biologically active recombinant proteins or genetically engineered derivatives of a variety of enzymes such as metalloproteinases and proprotein convertases, biologically active recombinant proteins or genetically engineered derivatives of several cell-surface receptors, adhesion molecules, signaling proteins and extracelluar-martix proteins, biologically active recombinant proteins or genetically engineered derivatives of proteins or fragments thereof for production of vaccines, biological active recombinant proteins or genetically engineered derivatives of any natural occurring of artificially designed proprotein or precursor protein which requires the action of a proprotein convertase for cleavage into biologically active components

Trademark Filing History

Description	Date	Event Coding
ASSIGNED TO EXAMINER	2001-07-17	1 DOCK D:Assigned to Examiner
NON-FINAL ACTION MAILED	2001-07-20	2 CNRT F:First Action
CORRESPONDENCE RECEIVED IN LAW OFFICE	2001-12-06	3 CRFA I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2002-02-05	4 CNSA P:
TEAS CHANGE OF CORRESPONDENCE RECEIVED	2002-04-18	5 TCCA I:Incoming Correspondence
NOTICE OF PUBLICATION	2002-06-26	6 NPUB O:Outgoing Correspondence
PREVIOUS ALLOWANCE COUNT WITHDRAWN	2002-08-21	7 ZZZX Z:Deletion
FINAL REFUSAL MAILED	2002-10-01	8 CNFR O:Outgoing Correspondence
CORRESPONDENCE RECEIVED IN LAW OFFICE	2003-03-19	9 CRFA I:Incoming Correspondence
ABANDONMENT - EXPRESS MAILED	2003-03-30	10 ABN1 O:Outgoing Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.